Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Biomaterials

Cresilon raises funds for bleeding-control hydrogel

by Michael McCoy
April 3, 2021 | A version of this story appeared in Volume 99, Issue 12

 

A close-up photo of manufacturing equipment.
Credit: Cresilon
A close-up of equipment at Cresilon's Brooklyn, New York, facility

Cresilon has raised $38.5 million in funding to expand production and launch of its plant-based hydrogel products, which stop traumatic bleeding on contact. Cresilon was cofounded in 2010 by Joe Landolina, then a chemical engineering undergraduate at New York University. Today, Cresilon’s Brooklyn, New York, facility produces its algae-derived product, Vetigel, for veterinary applications. Landolina says the firm is pursuing US approval for external human use.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.